A phase I trial investigating the safety and tolerability of single ascending doses of ALKS-7119 in healthy subjects
Phase of Trial: Phase I
Latest Information Update: 28 Apr 2016
At a glance
- Drugs ALKS 7119 (Primary)
- Indications Agitation
- Focus Adverse reactions; First in man
- Sponsors Alkermes plc
- 28 Apr 2016 Full results from this study, including unblinded safety data, are expected in the second half of 2016, according to an Alkermes media release.
- 28 Apr 2016 Preliminary data from the first six escalating dose cohorts published in an Alkermes media release.
- 25 Jan 2016 According to an Alkermes media release, results from this study are expected to be available in the second half of 2016.